Clinical trials: Mechanical Ventilation
Pulmonary Disease, Chronic Obstructive, Amyotrophic Lateral Sclerosis
European Home Mechanical Ventilation Registry
The European Home Mechanical Ventilation Registry (EHMVR) will enable a thorough evaluation of HMV by documenting the characteristics of HMV patients and their treatment.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Amyotrophic Lateral Sclerosis, Spinal Cord Injury, Muscular Dystrophies
- Trial name
- EHMVR (NCT02315339)
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- ResMed
Respiration, Artificial
Improvement of Weaning From Mechanical Ventilation by Continuous Ultrasound Monitoring of Diaphragm Excursion
Justification: The diaphragm is the main inspiratory muscle. Its dysfunction therefore compromises ventilation, which is necessary for gas exchange. Diaphragmatic dysfunction is frequently observed in resuscitation patients.
- Trial name
- WEAN-US (NCT04008875)
- Where
- 3 sites in France
- Volunteers
- 39 people
- Sponsor
- Respinor AS
COPD, Chronic Obstructive Pulmonary Disease
The PALP™-COPD Trial (Low-Flow CO2-Removal (ECCO2-R) in Exacerbated COPD)
A Multicenter, Randomized, Controlled Trial to Determine Safety and Efficacy of Pump Assisted Lung Protection (PALP™) for Low Flow Carbon Dioxide (CO2) Removal in Conjunction with Liberation from Mechanical Ventilation Compared…
- Trial name
- PALP-COPD (NCT02107222)
- Testing
- CO2-Removal (PALP-Device/MaquetCP)
- Where
- Germany
- Sponsor
- Maquet Cardiopulmonary GmbH
Respiration, Artificial
Continuous Measurement of Diaphragm Excursion as a Predictor of Extubation Failure
Background: Patients are put under invasive mechanical ventilation (MV) during respiratory failure because they can no longer breathe in a way that delivers enough oxygen to their body.
- Trial name
- NCT03896048
- Where
- Norway
- Volunteers
- 11 people
- Sponsor
- Respinor AS
Acute Hypoxemic Respiratory Failure
Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19
Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure…
- Trial name
- NCT04570384
- Testing
- L-Citrulline
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Asklepion Pharmaceuticals, LLC
Critical Illness
Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients
The purpose of this study is to determine whether the use of different sedatives affect the weaning process from mechanical ventilation in intensive care patients.
- Trial name
- NICEWEAN (NCT01707680)
- Testing
- SOC
- Where
- 3 sites in Sweden
- Volunteers
- 155 people
- Sponsor
- Orion Corporation, Orion Pharma
COVID-19, Severe Respiratory Distress Syndrome
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19.
- Conditions
- COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
- Trial name
- NCT07466524
- Testing
- suPARnostic® TurbiLatex Assay on Roche cobas c501
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- ViroGates A/S
Sedation
Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)
This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU)…
- Trial name
- INSPiRE-ICU1 (NCT05312385)
- Testing
- Isoflurane, Propofol, Isoflurane (run-ins)
- Where
- 14 sites in United States
- Volunteers
- 277 people
- Sponsor
- Sedana Medical
Ventilator-induced Diaphragm Dysfunction, VIDD
Evaluation of heepSync, a Novel Algorithm for Transcutaneous Electrical Stimulation of Respiratory Muscles in Mechanically Ventilated Patients.
Up to 76% of ICU patients on mechanical ventilation develop significant respiratory muscle atrophy within the first 24 hours, contributing to prolonged ventilation, increased morbidity, and higher healthcare costs.
- Conditions
- Ventilator-induced Diaphragm Dysfunction, VIDD, Weaning Failure
- Trial name
- NCT07363902
- Testing
- Heecap
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Tesai Care SL
Sedation in the ICU
A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU
The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for prolonged sedation(≥72h) during mechanical ventilation in the ICU.
- Trial name
- NCT05913336
- Testing
- Remimazolam Tosilate
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Viral Pneumonia
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection.
- Trial name
- INVENT (NCT06999603)
- Testing
- SNG001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Synairgen Research Ltd.
Analgesia
Comparison of Analgesic Effect and Prognosis of Butorphanol and Fentanyl in Patients With Mechanical Ventilation
ICU patients often in a strong stress environment. Various invasive procedures such as wound dressing change, sputum suction,Pull out the thoracic duct etc.
- Trial name
- NCT04315935
- Testing
- Butorphanol and Propofol, Fentanyl and Propofol
- Where
- China
- Volunteers
- 355 people
- Sponsor
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
Pneumonia, Bacterial
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and…
- Trial name
- INHALE 1 (NCT01799993)
- Testing
- Amikacin Inhalation Solution (BAY41-6551)
- Where
- 65 sites in United States, Australia and 10 more
- Volunteers
- 725 people
- Sponsor
- Bayer
Severe Sepsis
S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT
The purpose of this study is to determine if Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) therapy is effective in the treatment of severe sepsis.
- Trial name
- SAFEbt (NCT01312675)
- Testing
- S.A.F.E.BT
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- B. Braun Medical Inc.
Sedation
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU…
- Trial name
- NCT00158873
- Testing
- midazolam, lorazepam, fentanyl
- Where
- 15 sites in Netherlands
- Volunteers
- 224 people
- Sponsor
- GlaxoSmithKline
COVID-19
Beta-glucans for Hospitalised Patients With COVID-19
This randomised trial aims to assess the role of beta1-3 glucan supplementation in improving clinical symptoms and other outcomes amongst hospitalised patients with COVID-19.
- Trial name
- NCT05465798
- Testing
- MC 3x3
- Where
- Chile
- Volunteers
- 60 people
- Sponsor
- Wohlstand Pharmaceutical
Critical Illness, Hyperglycemia
Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia
The aim of the study is to evaluate the beneficial effects of the administration of a complete diet rich in monounsaturated fatty acids (MUFA) and slow absorption carbohydrate in patients with stress hyperglycemia(T-Diet Plus…
- Conditions
- Critical Illness, Hyperglycemia, Dietary Modification, Metabolic Stress Hyperglycemia
- Trial name
- NCT01233726
- Testing
- T-Diet plus Diabet IR, ISOSOURCE PROTEIN FIBRE, GLUCERNA SELECT
- Where
- 2 sites in Spain
- Volunteers
- 159 people
- Sponsor
- Vegenat, S.A.
Acute Exacerbation of COPD
Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD
This study evaluates the safety and efficacy of using the Hemolung RAS to provide low-flow extracorporeal carbon dioxide removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients who require…
- Trial name
- VENT-AVOID (NCT03255057)
- Testing
- Hemolung Respiratory Assist System, Invasive mechanical ventilation
- Where
- 32 sites in United States
- Volunteers
- 113 people
- Sponsor
- Alung Technologies
Critical Illness, Mechanical Ventilation
Proof of Concept Trial to Confirm That the Recovery of Patients Treated in the Intensive Care Unit Requiring Mechanical Ventilation is Beneficially Affected by the Environmental Simulation of Daytime and Night Time Alternation as Well as by the Nutrition Protocol Corresponding to the Daily Rhythm
The purpose of this study is to determine whether the environmental simulation of daytime and night time alternation as well as by the nutrition protocol corresponding to the daily rhythm are beneficially affect the recovery of…
- Trial name
- NCT02828722
- Testing
- Controlled light and noise, Controlled nutrition
- Where
- Hungary
- Volunteers
- 45 people
- Sponsor
- Achros Health Technologies Corporation
COVID-19, Undefined
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired…
- Trial name
- NCT04659122
- Testing
- AT-100
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Airway Therapeutics, Inc.